In Cellulo Examination of a Beta-Alpha Hybrid Construct of Beta-Hexosaminidase A Subunits, Reported to Interact with the GM2 Activator Protein and Hydrolyze GM2 Ganglioside

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Sinici, Incilay ^a   Yonekawa, Sayuri ^b   Tkachyova, Ilona ^b,c   Gray, Steven J ^d   Samulski, R Jude ^d   Wakarchuk, Warren ^e   Mark, Brian L ^f   Mahuran, Don J ^b,c  

^a HACETTEPE UNIVERSITY   (Turkey)

^b HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e RYERSON UNIVERSITY   (Canada)

^f UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA N ACETYLHEXOSAMINIDASE A; BETA N ACETYLHEXOSAMINIDASE BETA CHAIN; GANGLIOSIDE GM2; GANGLIOSIDE GM2 ACTIVATOR PROTEIN; GANGLIOSIDE GM3; HYBRID PROTEIN;

ANIMAL CELL; ARTICLE; CELL LINE; CONTROLLED STUDY; CRYSTAL STRUCTURE; EXPRESSION VECTOR; FIBROBLAST; HUMAN; HUMAN CELL; HYDROLYSIS; LYSOSOME; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN STRUCTURE; TISSUE CULTURE; WESTERN BLOTTING;

AMINO ACID SUBSTITUTION; ANIMALS; BETA-N-ACETYLHEXOSAMINIDASES; BLOTTING, WESTERN; CATS; CHROMATOGRAPHY, ION EXCHANGE; CHROMATOGRAPHY, THIN LAYER; G(M2) ACTIVATOR PROTEIN; G(M2) GANGLIOSIDE; HUMANS; HYDROLYSIS; MICE; PROTEIN BINDING; PROTEIN SUBUNITS; RECOMBINANT PROTEINS; SANDHOFF DISEASE; TAY-SACHS DISEASE; TRANSFECTION;

EID: 84874605222     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057908     Document Type: Article

References (40)

1. Mahuran DJ, (1991) The Biochemistry of HEXA and HEXB Gene Mutations Causing GM2 Gangliosidosis. Biochim Biophys Acta 1096: 87-94.
2. Mark BL, Mahuran DJ, Cherney MM, Zhao D, Knapp S, et al. (2003) Crystal structure of human beta-hexosaminidase B: understanding the molecular basis of Sandhoff and Tay-Sachs disease. J Mol Biol 327: 1093-1109.
3. Maier T, Strater N, Schuette CG, Klingenstein R, Sandhoff K, et al. (2003) The X-ray crystal structure of human beta-hexosaminidase B provides new insights into Sandhoff disease. J Mol Biol 328: 669-681.
4. Lemieux MJ, Mark BL, Cherney MM, Withers SG, Mahuran DJ, et al. (2006) Crystallographic Structure of Human beta-Hexosaminidase A: Interpretation of Tay-Sachs Mutations and Loss of G(M2) Ganglioside Hydrolysis. J Mol Biol 359: 913-929.
5. Wright CS, Li SC, Rastinejad F, (2000) Crystal structure of human GM2-activator protein with a novel beta-cup topology. J Mol Biol 304: 411-422.
6. Sharma R, Deng H, Leung A, Mahuran D, (2001) Identification of the 6-Sulfate Binding Site Unique to α-Subunit-Containing Isozymes of Human beta-Hexosaminidase. Biochemistry 40: 5440-5446.
7. Sharma R, Bukovac S, Callahan J, Mahuran D, (2003) A single site in human beta-hexosaminidase A binds both 6-sulfate-groups on hexosamines and the sialic acid moiety of GM2 ganglioside. Biochim Biophys Acta 1637: 113-118.
8. Hasilik A, Neufeld EF, (1980) Biosynthesis of lysosomal enzymes in fibroblasts: synthesis as precursors of higher molecular weight. J Biol Chem 255: 4937-4945.
9. Mahuran DJ, Neote K, Klavins MH, Leung A, Gravel RA, (1988) Proteolytic processing of pro-alpha and pro-beta precursors from human beta-hexosaminidase. Generation of the mature alpha and beta-a beta-b subunits. J Biol Chem 263: 4612-4618.
10. Korneluk RG, Mahuran DJ, Neote K, Klavins MH, O'Dowd BF, et al. (1986) Isolation of cDNA clones coding for the alpha-subunit of human beta- hexosaminidase. Extensive homology between the alpha- and beta-subunits and studies on Tay-Sachs disease. J Biol Chem 261: 8407-8413.
11. Zarghooni M, Bukovac S, Tropak M, Callahan J, Mahuran D, (2004) An alpha-subunit loop structure is required for GM2 activator protein binding by beta-hexosaminidase A. Biochem Biophy Res Com. 324: 1048-1052.
12. Matsuoka K, Tamura T, Tsuji D, Dohzono Y, Kitakaze K, et al. (2011) Therapeutic potential of intracerebroventricular replacement of modified human beta-hexosaminidase B for GM2 gangliosidosis. Mol Ther 19: 1017-1024.
13. Cachon-Gonzalez MB, Wang SZ, Lynch A, Ziegler R, Cheng SH, et al. (2006) Effective gene therapy in an authentic model of Tay-Sachs-related diseases. Proc Natl Acad Sci (USA) 103: 10373-10378.
14. Guidotti JE, Mignon A, Haase G, Caillaud C, McDonell N, et al. (1999) Adenoviral gene therapy of the Tay-Sachs disease in hexosaminidase A-deficient knock-out mice. Hum Mol Genet 8: 831-838.
15. Martino S, Marconi P, Tancini B, Dolcetta D, De Angelis MG, et al. (2005) A direct gene transfer strategy via brain internal capsule reverses the biochemical defect in Tay-Sachs disease. Hum Mol Genet 14: 2113-2123.
16. Gray SJ (2012) Gene therapy and neurodevelopmental disorders. Neuropharmacology in press.
17. Bevan AK, Duque S, Foust KD, Morales PR, Braun L, et al. (2011) Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol Ther 19: 1971-1980.
18. Federici T, Taub JS, Baum GR, Gray SJ, Grieger JC, et al. (2012) Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs. Gene Ther 19: 852-859.
19. Gray SJ, Matagne V, Bachaboina L, Yadav S, Ojeda SR, et al. (2011) Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther 19: 1058-1069.
20. Samaranch L, Salegio EA, San Sebastian W, Kells AP, Foust KD, et al. (2012) Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum Gene Ther 23: 382-389.
21. Duque S, Joussemet B, Riviere C, Marais T, Dubreil L, et al. (2009) Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther 17: 1187-1196.
22. Lacorazza HD, Flax JD, Snyder EY, Jendoubi M, (1996) Expression of human beta-hexosaminidase alpha-subunit gene (the gene defect of Tay-Sachs disease) in mouse brains upon engraftment of transduced progenitor cells. Nature Med 2: 424-429.
23. Tropak MB, Bukovac SW, Rigat BA, Yonekawa S, Wakarchuk W, et al. (2010) A sensitive fluorescence-based assay for monitoring GM2 ganglioside hydrolysis in live patient cells and their lysates. Glycobiology 20: 356-365.
24. Smiljanic-Georgijev N, Rigat B, Xie B, Wang W, Mahuran DJ, (1997) Characterization of the affinity of the GM2 activator protein for glycolipids by a fluorescene dequenching assay. Biochim Biophys Acta 1339: 192-202.
25. Martin DR, Krum BK, Varadarajan GS, Hathcock TL, Smith BF, et al. (2004) An inversion of 25 base pairs causes feline GM2 gangliosidosis variant. Exp Neurol 187: 30-37.
26. Fernandes MJG, Yew S, Leclerc D, Henrissat B, Vorgias CE, et al. (1997) Identification of candidate active site residues in lysosomal beta-hexosaminidase A. J Biol Chem. 272: 814-820.
27. Hou Y, McInnes B, Hinek A, Karpati G, Mahuran D, (1998) A Pro504Ser substitution in the β-subunit of β-hexosaminidase A inhibits alpha-subunit hydrolysis of GM2 ganglioside, resulting in chronic Sandhoff disease. J Biol Chem 273: 21386-21392.
28. Rempel BP, Withers SG, (2008) Covalent inhibitors of glycosidases and their applications in biochemistry and biology. Glycobiology 18: 570-586.
29. Folch J, Lees M, Sloane Stanley GH, (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226: 497-509.
30. Hirabayashi Y, Li Y-T, Li S-C, (1983) The protein activator specific for the enzymic hydrolysis of GM2 ganglioside in normal human brain and brains of three types of GM2 gangliosidosis. J Neurochem 40: 168-175.
31. Yuziuk JA, Bertoni C, Beccari T, Orlacchio A, Wu YY, et al. (1998) Specificity of mouse GM2 activator protein and beta-N-acetylhexosaminidases A and B. Similarities and differences with their human counterparts in the catabolism of GM2. J Biol Chem 273: 66-72.
32. Sango K, Yamanaka S, Hoffmann A, Okuda Y, Grinberg A, et al. (1995) Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism. Nature Genet 11: 170-176.
33. Phaneuf D, Wakamatsu N, Huang JQ, Borowski A, Peterson AC, et al. (1996) Dramatically different phenotypes in mouse models of human Tay-Sachs and Sandhoff diseases. Hum Mol Genet 5: 1-14.
34. Liu YJ, Hoffmann A, Grinberg A, Westphal H, McDonald MP, et al. (1997) Mouse model of GM2 activator deficiency manifests cerebellar pathology and motor impairment. Proc Natl Acad Sci (USA) 94: 8138-8143.
35. Bertoni C, Li YT, Li SC, (1999) Catabolism of asialo-GM2 in man and mouse. Specificity of human/mouse chimeric GM2 activator proteins. J Biol Chem 274: 28612-28618.
36. Callahan JW, Pinsky L, Wolfe LS, (1970) GM1-gangliosidosis (Type II): studies on a fibroblast cell strain. Biochem Med 4: 295-316.
37. Igdoura SA, Mertineit C, Trasler JM, Gravel RA, (1999) Sialidase-mediated depletion of GM2 ganglioside in Tay-Sachs neuroglia cells. Hum Mol Genet 8: 1111-1116.
38. Suzuki Y, Nakamura N, Fukuoka K, (1978) GM1-gangliosidosis- accumulation of ganglioside-GM1 in cultured skin fibroblasts and correlation with clinical types. Hum Genet 43: 127-131.
39. Neote K, Brown CA, Mahuran DJ, Gravel RA, (1990) Translation initiation in the HEXB gene encoding the beta-subunit of human beta-hexosaminidase. J Biol Chem 265: 20799-20806.
40. Tropak MB, Reid S, Guiral M, Withers SG, Mahuran DJ, (2004) Pharmacological enhancement of β-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff patients. J Biol Chem 279: 13478-13487.